Table 1 Patient, tumor, and treatment characteristics of 322 patients
Characteristics | N (%) |
|---|---|
Age, years | |
Median, range | 51 (23~79) |
T stage | |
Tis | 50 (15.5 %) |
T1 (≤2 cm) | 189 (58.7 %) |
T2 (>2 and ≤5 cm) | 83 (25.8 %) |
N stage | |
N0 | 239 (78.1 %) |
N1 | 55 (18.0 %) |
N2 | 12 (3.9 %) |
AJCC stage | |
0 | 50 (15.5 %) |
I–IIA | 233 (72.4 %) |
IIB–IIIA | 39 (12.1 %) |
Histology | |
Ductal in situ | 50 (15.5 %) |
Invasive ductal | 244 (75.8 %) |
Invasive lobular | 7 (2.2 %) |
Others | 21 (6.5 %) |
Hormonal receptor | |
Positive | 238 (82.1 %) |
Negative | 49 (16.9 %) |
HER2 | |
Negative | 235 (73.0 %) |
Positive | 40 (12.4 %) |
Ki-67 | |
Negative | 139 (43.2 %) |
Positive | 173 (53.7 %) |
Nuclear grade | |
Low | 38 (11.8 %) |
Intermediate | 170 (52.8 %) |
High | 114 (35.4 %) |
Resection margin status | |
Negative | 310 (96.3 %) |
Close | 5 (1.6 %) |
Positive | 7 (2.2 %) |
Hormonal therapy | |
Done | 236 (73.3 %) |
Not done | 86 (26.7 %) |
Chemotherapy | |
Done | 198 (61.5 %) |
Not done | 124 (38.5 %) |
Radiotherapy | |
Done | 310 (96.3 %) |
Not done | 12 (3.7 %) |